Abstract
The overall goal of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) is to optimize and validate biomarkers for clinical trials while sharing all data and biofluid samples with the global scientific community. ADNI has been instrumental in standardizing and validating amyloid beta (Aβ) and tau positron emission tomography (PET) imaging. ADNI data were used for the US Food and Drug Administration (FDA) approval of the Fujirebio and Roche Elecsys cerebrospinal fluid diagnostic tests. Additionally, ADNI provided data for the trials of the FDA-approved treatments aducanumab, lecanemab, and donanemab.
More than 6000 scientific papers have been published using ADNI data, reflecting ADNI’s promotion of open science and data sharing. Despite its enormous success, ADNI has some limitations, particularly in generalizing its data and findings to the entire US/Canadian population. This introduction provides a historical overview of ADNI and highlights its significant accomplishments and future vision to pioneer “the clinical trial of the future” focusing on demographic inclusivity.
Highlights
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) introduced a novel model for public-private partnerships and data sharing.
It successfully validated amyloid and Tau PET imaging, as well as CSF and plasma biomarkers, for diagnosing Alzheimer’s disease.
ADNI generated and disseminated vital data for designing AD clinical trials.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Michael W. Weiner,
Shaveta Kanoria,
Melanie J. Miller,
Paul S. Aisen,
Laurel A. Beckett,
Catherine Conti,
Adam Diaz,
Derek Flenniken,
Robert C. Green,
Danielle J. Harvey,
Clifford R. Jack Jr.,
William Jagust,
Edward B. Lee,
John C. Morris,
Kwangsik Nho,
Rachel Nosheny,
Ozioma C. Okonkwo,
Richard J. Perrin,
Ronald C. Petersen,
Monica Rivera‐Mindt,
Andrew J. Saykin,
Leslie M. Shaw,
Arthur W. Toga,
Duygu Tosun,
Dallas P. Veitch,
for the Alzheimer’s Disease Neuroimaging Initiative | December 23, 2024